SCHEMBL6502168

SCHEMBL6502168

Cc1ccc(-c2ccc(C)cc2C(=O)Nc2ccc(NCCc3csc(C)n3)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.51
RAB9A P51151 9/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
ALDH1A1 P00352 3/20 0.51
MAPT P10636 5/20 0.50
KDM4E B2RXH2 3/20 0.50
STAT1 P42224 2/20 0.46
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPK1 P28482 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NAMPT P43490 2/20 0.43
TP53 P04637 4/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6499843 0.94 SMN1; SMN2 (0.47) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6497710 0.93 POLB (0.49) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6499732 0.92 NPC1 (0.51) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6501075 0.90 RAB9A (0.43) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6795866 0.90 NPC1 (0.53) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6489811 0.87 GCGR (0.51) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6499318 0.85 MAPT (0.49) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6498250 0.85 POLB (0.49) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6490142 0.85 POLB (0.43) NPC1RAB9AALDH1A1MAPTKDM4E
SCHEMBL6501243 0.84 NPC1 (0.39) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 NPC1 100/4885RAB9A 4382/4885SMN1; SMN2 1921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.